(Q67215225)
English
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
scholarly article by P LeWitt et al published 1997 in Movement Disorders
- The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol
Statements
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. (English)
0 references
1997
0 references